Deciphera LogoON. Friday, May 15th, the FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST. Press release

QINLOCK represents a well-tolerated and new treatment option designed specifically for people with GIST. QINLOCK was proven to give patients in our clinical study significantly more time living without tumors growing or spreading (median1 progression-free survival of 6.3 months versus 1.0 month for placebo). The most common side effects included, but are not limited to, hair thinning or hair loss, tiredness, nausea, abdominal pain and constipation. Other important risks include a skin problem called palmar-plantar erythrodysesthesia syndrome, high blood pressure, and certain heart problems. See below for complete Important Safety Information.

Deciphera is committed to supporting GIST patients and removing barriers to access our medicine. As part of that commitment, we have established Deciphera AccessPoint, a patient support program to provide access and affordability solutions for eligible individuals receiving QINLOCK. For more information, visit

Read more about ripretinib.